Welcome to our dedicated page for Alpha Cognition news (Ticker: ACOG), a resource for investors and traders seeking the latest updates and insights on Alpha Cognition stock.
Alpha Cognition Inc (ACOG) is a clinical-stage biopharmaceutical company advancing novel treatments for Alzheimer's disease and cognitive impairments linked to mild traumatic brain injury. This page provides investors and medical professionals with essential updates on therapeutic developments, regulatory milestones, and strategic initiatives in neurodegenerative care.
Find timely updates on clinical trial progress, FDA communications, and research partnerships directly from the company. Our curated news collection simplifies tracking of ACOG's pipeline candidates, including therapies targeting unmet needs in neurological disorders.
Key updates include developments in Phase 2/3 clinical studies, intellectual property expansions, and manufacturing scale-up announcements. All content is sourced from official releases to ensure compliance with financial disclosure standards.
Bookmark this page for streamlined access to verified ACOG developments. Check back regularly for critical updates impacting the company's position in the $1.3 trillion global neurology market.
Alpha Cognition (NASDAQ: ACOG) has announced its upcoming participation in the D. Boral Capital Inaugural Global Conference. The event is scheduled for May 14, 2025, at The Plaza Hotel in New York City.
Company CEO Michael McFadden will be available for one-on-one meetings throughout the conference day from 9:00 A.M. to 3:00 P.M. (ET). Interested parties who wish to schedule meetings with the management team can make arrangements by contacting John Perez at jperez@dboralcapital.com.
This conference participation represents an opportunity for investors and stakeholders to engage directly with Alpha Cognition's leadership and learn more about the company's developments and strategies.
Alpha Cognition (NASDAQ: ACOG) announced three upcoming presentations at the 2025 Alzheimer's Association International Conference (AAIC) in Toronto, showcasing clinical data for ZUNVEYL (benzgalantamine). The presentations will focus on bioequivalence studies that were important for the drug's FDA approval in July 2024 and commercial launch in March 2025.
ZUNVEYL, a twice-daily treatment for mild-to-moderate Alzheimer's disease, targets the long-term care market valued at $2 billion annually in the United States. The drug enhances cholinergic function to support memory, learning, and cognitive function. The company will present data on bioequivalence to Galantamine ER and IR, along with dose proportionality studies across the 5-15 mg range.
Alpha Cognition (NASDAQ: ACOG) demonstrated significant growth in 2024, successfully raising $52.8 million and completing its NASDAQ uplisting. The company achieved several key milestones, including completing commercial manufacturing for its lead product ZUNVEYL (benzgalantamine), securing a U.S. patent extending protection through 2044, and finalizing phase one of a Department of Defense-funded study for head trauma treatment.
Notable achievements include a successful launch in the U.S. Long-Term Care (LTC) market, estimated at $2 billion, and securing a $44 million licensing agreement for Asia. The company reports positive initial physician feedback and is actively building international partnerships to diversify revenue streams.
Alpha Cognition (ACOG) reported its Q4 and full-year 2024 financial results, highlighting a successful quarter with $52.8 million raised to support ZUNVEYL's commercial launch and Nasdaq uplisting. The company ended 2024 with $48.6 million in cash, projecting a two-year runway.
Key developments include completing commercial manufacturing for ZUNVEYL's launch, successful pre-clinical bomb-blast study results, and signing a $44 million distribution deal with China Medical System Holdings. The company secured new patent protection for ZUNVEYL through 2044 in the US.
Financial results show Q4 2024 R&D expenses of $1.0M and G&A expenses of $1.5M. Full-year 2024 resulted in a net loss of $14.6 million ($2.02 per share), compared to $13.8 million loss in 2023. The company launched ZUNVEYL in the US market in March 2025 with an experienced commercial team.
Alpha Cognition (Nasdaq: ACOG), a biopharmaceutical company focused on neurodegenerative disease treatments, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for March 31, 2025, after market close.
The company will host a conference call at 4:30pm ET to discuss financial and operating results. Investors can participate via phone (1-877-407-9039 or 1-201-689-8470) or through a live audio webcast. A Call me™ feature is available to avoid operator wait times, and an audio replay will be accessible through provided contact numbers and access ID: 13752398.
Alpha Cognition (Nasdaq: ACOG) has officially launched ZUNVEYL (Benzgalantamine), the first FDA-approved oral treatment for mild to moderate Alzheimer's disease in the past decade. The company has deployed a 32-person sales team targeting the $2 billion Long-Term-Care market.
The commercial team, averaging 16 years of industry sales experience and 10 years in long-term care, is now actively engaging with healthcare providers nationwide. ZUNVEYL is available in three doses (5 mg, 10 mg, and 15 mg) through pharmacies across the country.
Lauren D'Angelo, Chief Operating Officer and Chief Commercial Officer, emphasized that all launch activities were delivered on-time and on-budget, positioning ZUNVEYL for success in providing a differentiated treatment option for Alzheimer's patients.
Alpha Cognition (NASDAQ: ACOG) has been granted a new patent by the USPTO titled 'Coated Tablets for pH-Dependent Release of Benzgalantamine.' The patent strengthens the company's intellectual property portfolio by protecting tablet formulations of benzgalantamine, extending ZUNVEYL's patent protection in the United States through 2044.
ZUNVEYL, a novel treatment for mild to moderate Alzheimer's disease, is designed to improve patient outcomes through optimized drug delivery. The company plans to launch ZUNVEYL in U.S. pharmacies in Q1 2025, where it will be available by prescription nationwide.
Alpha Cognition Inc. (NASDAQ: ACOG) has achieved significant milestones in 2024, including FDA approval for its Alzheimer's therapy ZUNVEYL (benzgalantamine), a successful $4.5M financing round, and NASDAQ listing preparations. The company is positioned to launch ZUNVEYL in Q1 2025, with sales force and commercial production already in place.
ZUNVEYL targets the long-term care (LTC) market, which represents a $2 billion addressable market and 36% of Alzheimer's prescriptions. The drug's prodrug mechanism improves patient outcomes by reducing common side effects like nausea and insomnia. Additionally, Alpha Cognition has secured a $44M licensing agreement with China Medical Systems Holdings.
Alpha Cognition (NASDAQ: ACOG) has announced strategic appointments to strengthen its commercial and medical teams ahead of the ZUNVEYL launch, its treatment for mild to moderate Alzheimer's disease, planned for Q1 2025. The company has appointed:
- Jen Pesa as VP of Commercial, bringing 25 years of pharmaceutical experience and 12 successful product launches
- Jack Kelly as Head of Market Access, with 30+ years in pharmaceutical industry
- Rommel Fernandez as VP of Corporate Strategy and Operations, with 17 years of experience in pharma and biotech
- Kurt Grady as VP of Medical Affairs, bringing 30 years of healthcare experience
These appointments aim to build the commercial infrastructure necessary for ZUNVEYL's nationwide pharmacy launch, with particular focus on the long-term care (LTC) segment.
Alpha Cognition (ACOG) has entered into a $44 million exclusive licensing agreement with China Medical System Holdings for ZUNVEYL (benzgalantamine) in Asia (excluding Japan), Australia, and New Zealand. The agreement includes $6 million in upfront payments plus development and commercial milestone payments, along with royalties on net sales.
ZUNVEYL, an FDA-approved oral treatment for mild-to-moderate Alzheimer's disease, will be developed, manufactured, and commercialized by CMS in the licensed territories. The target market includes an estimated 50 million people with Alzheimer's disease in the region. Alpha Cognition maintains its plans for a U.S. launch in Q1 2025.
FAQ
What is the current stock price of Alpha Cognition (ACOG)?
What is the market cap of Alpha Cognition (ACOG)?
